About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Department of Neurology-Neuroimmunology
›
top-articles
Department of Neurology-Neuroimmunology
20
(top 2%)
papers
1.3K
(top 2%)
citations
13
(top 2%)
h
-index
21
(top 2%)
g
-index
22
all documents
1.4K
doc citations
452
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Multiple Sclerosis Journal
2018
458
2
ECTRIMS
/
EAN
guideline on the pharmacological treatment of people with multiple sclerosis
European Journal of Neurology
2018
147
3
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
Journal of Neurology, Neurosurgery and Psychiatry
2016
137
4
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study
JAMA Neurology
2021
132
5
Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
Annals of Neurology
2021
123
6
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper
Multiple Sclerosis Journal
2016
118
7
Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study
Journal of Medical Internet Research
2019
90
8
Sex effects across the lifespan in women with multiple sclerosis
Therapeutic Advances in Neurological Disorders
2020
58
9
Targeting Inflammasomes to Treat Neurological Diseases
Annals of Neurology
2021
46
10
Natalizumab: Risk Stratification of Individual Patients with Multiple Sclerosis
CNS Drugs
2014
24
11
Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
PLoS ONE
2013
23
12
HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis
Journal of Medical Genetics
2014
19
13
Matrix metalloproteinase 9 is decreased in natalizumab‐treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy
Annals of Neurology
2017
14
14
Classic Block Design “Pseudo”‐Resting‐State fMRI Changes After a Neurorehabilitation Program in Patients with Multiple Sclerosis
Journal of Neuroimaging
2018
14
15
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis
Journal of Neurology, Neurosurgery and Psychiatry
2023
9
16
Nerve Conduction Velocity Is Regulated by the Inositol Polyphosphate-4-Phosphatase II Gene
American Journal of Pathology
2014
8
17
Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe
Journal of the Neurological Sciences
2015
8
18
CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald Criteria 2010: No
Multiple Sclerosis Journal
2013
6
19
A new cognitive rehabilitation programme for patients with multiple sclerosis: the ‘MS-line! Project’
Multiple Sclerosis Journal
2015
3
20
Neurotoxicity‐associated sinus bradycardia after chimeric antigen receptor T‐cell therapy
Hematological Oncology
2022
2
21
Possible new modifications for the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis
Multiple Sclerosis Journal
2013
0
site/software ©
exaly
; All materials licenced under
CC by-SA
.